Jul 2026· Journal of Immunology· Vol 215· 0 citations
TL;DR
It is found that TSC in chronic infection harbor a LEF1+ TSC pool sharing the core stemness epigenetic and molecular program observed in autoimmune LEF1+ TSC, discovering LEF1 as the master regulator defining T cell stemness and identify novel targets for therapeutic intervention.
Abstract
In autoimmunity and chronic infection, both settings of persistent (self or foreign) antigen, immune responses are sustained by stem-like CD8 T cells, which self-renew and give rise to differentiated progeny. However, if and how T stemness is epigenetically encoded, which transcription factor(s) regulate the stem-T cells, and whether the stem-T cell state is disease-specific or shared across diseases, is currently not known.
We used clinically relevant models of autoimmune type 1 diabetes (T1D) and chronic infection and conducted serial T cell transplantation studies in vivo, combined with single cell paired RNA- and ATAC-sequencing on antigen-specific T cells. We developed CRISPR/Cas9-mediated gene-editing approaches in primary T cells as well as CUT&RUN studies, identifying a novel hierarchy of transcription factors regulating stem T cell identity and function.
We discovered that a small subset of stem-T cells (TSC) express lymphoid enhancer-binding factor 1 (LEF1), a member of the TCF/LEF TF family. Paired single cell transcriptomic and epigenomic analyses reveal that the LEF1+ TSC harbor a unique epigenetically encoded molecular state enriched in genes and pathways characteristic of embryonic and adult (somatic) stem cells (e.g. neural stem cells). Strikingly, we found that TSC in chronic infection harbor a LEF1+ TSC pool sharing the core stemness epigenetic and molecular program observed in autoimmune LEF1+ TSC. Loss- and gain-of-function studies in both autoimmune T1D and chronic infection confirmed the critical role of LEF1 in maintaining T cell stemness. CUT&RUN analyses provide clues as to how LEF1 instructs the epigenetically encoded program of stem-T cells.
Here we reveal novel insights into the molecular circuitries of CD8 T cell stemness and differentiation. We discover LEF1 as the master regulator defining T cell stemness and identify novel targets for therapeutic intervention.
NIH R01AI173249, JDRF SRA-2023-1410-S-B, MSKCC Basic Research Innovation Award, The Hearst Foundation
Lymphocyte Differentiation and Peripheral Maintenance (LYM)
Novel transcriptional regulators and niche-dependent signals that determine autoimmune T cell stemness and differentiation are identified, opening novel therapeutic avenues for the prevention and treatment of T1D and other autoimmune diseases.
S. Miakicheva, Katrina M. Hawley, P. Zumbo et al.· Journal of Immunology· 0 citations
These findings identify a novel microbial SCFA as a potential metabolic-epigenetic regulator, capable of reactivating effector programs in TEX cells while blocking terminal exhaustion, and provide insights into developing new therapeutic approaches to reprogram TEX cells and enhance the efficacy of T cell immunotherapy...
Asmaa M. Yousif, Amira Yousif, Ava Lowin et al.· Journal of Immunology· 0 citations
A revised view of iNKT cells as dynamic and context-dependent transcriptional states shaped by developmental history, tissue environment, antigen exposure, and species-specific regulatory programs is supported.
Meng Zhao, Lihua Wu· Frontiers in Immunology· 0 citations
stem-like CD4 biology is presented as an emerging framework and established observations from working models are distinguished and established observations from working models are distinguished.
Jia-Xiang Xu, Yun-Chao Yang, Jun Zhang et al.· Frontiers in Immunology· 0 citations
Genetic Id2 loss uncouples Tfh differentiation from effector activity, positioning Id2 inhibition as a novel therapeutic strategy to selectively disrupt pathogenic Tfh-GCB crosstalk in cGVHD.
Yujie Zhao, Eun Ko, Cameron McDonald-Hyman et al.· Journal of Immunology· 0 citations
This emerging view frames exhaustion as a context-dependent extension of the memory program rather than its collapse, and highlights how these insights can inform new approaches to manipulate T cell fate for therapeutic benefit.
Daniel T. Utzschneider, Stephen J. Turner· Trends in immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.